SNPMiner Trials by Shray Alag


SNPMiner Trials: Clinical Trial Report


Report for Clinical Trial NCT01015963

Developed by Shray Alag, 2019.
SNP Clinical Trial Gene

A Study of the Docetaxel Pharmacodynamics and Polymorphisms in ABCC2 and SLC01B3 in Caucasian and African-American Cancer Patients

This research trial studies deoxyribonucleic acid (DNA) in blood samples from Caucasian and African-American cancer patients who received docetaxel on clinical trial CLB-9871. Studying samples of blood from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. It may also help doctors learn more about how docetaxel is used by the body.

NCT01015963 Bladder Cancer Breast Cancer Head and Neck Cancer Lung Cancer Unspecified Adult Solid Tumor, Protocol Specific
MeSH: Breast Neoplasms Lung Neoplasms Head and Neck Neoplasms Urinary Bladder Neoplasms
HPO: Bladder neoplasm Breast carcinoma Neoplasm of head and neck Neoplasm of the breast Neoplasm of the lung

1 Interventions

Name: laboratory biomarker analysis

Description: Perform DNA sample analysis

Type: Other

Ancillary-correlative (DNA sample analysis)


Primary Outcomes

Measure: Incidence of ABBC2 polymorphism (rs12762549) and a SLC01B3 polymorphism (rs11045585) with docetaxel exposure

Time: Up to 2 years

Measure: Incidence of SLC01B3 polymorphism (rs11045585)

Time: Up to 2 years

Secondary Outcomes

Measure: Incidence of grade III/IV leukopenia/neutropenia (induced by docetaxel)

Time: Up to 2 years

Time Perspective: Retrospective

Case-Only


There are 2 SNPs

SNPs


1 rs11045585

Incidence of ABBC2 polymorphism (rs12762549) and a SLC01B3 polymorphism (rs11045585) with docetaxel exposure.

Incidence of SLC01B3 polymorphism (rs11045585).


2 rs12762549

Incidence of ABBC2 polymorphism (rs12762549) and a SLC01B3 polymorphism (rs11045585) with docetaxel exposure.



HPO Nodes


HPO:
Bladder neoplasm
Genes 22
PTEN HRAS APC KRAS RB1 AAGAB FLCN PIK3CA COL14A1 RNF43 AKT1 EP300 NTHL1 FGFR3 AXIN2 ATP7A SRC CTNNB1 DLC1 BUB1B NRAS DCC
Breast carcinoma
Genes 51
RAD51 RAD51C RAD51D CDKN2A KRAS MRE11 SLC22A18 STK11 MSH6 KLLN BRIP1 BRCA1 ATR BRCA2 PIK3CA PPM1D POLD1 NTHL1 POLE ESR1 WRN CHEK2 APC BARD1 MLH1 NBN COL14A1 AKT1 PRKN MSH2 FGFR2 IDH1 IDH2 CTNNB1 RB1CC1 PTEN MDM2 AAGAB CDH1 RNF43 PALLD PALB2 OPCML SEC23B TP53 SDHB SDHC SDHD SMAD4 TWIST1 RAD50
Neoplasm of head and neck
Genes 21
ASCC1 FOXE1 MSR1 RNF6 RHBDF2 APC PDGFRA CTHRC1 KIT TGFBR2 STK11 HABP2 DLEC1 STAT1 SDHA SDHB SDHC MINPP1 WWOX RAD21 FH
Neoplasm of the breast
Genes 73
RAD51 RAD51C RAD51D CDKN2A KRAS CDKN2B CDKN2D MRE11 SLC22A18 STK11 MSH6 RASGRP1 KLLN BRIP1 MGMT BRCA1 LMNA ATR ACD BRCA2 PIK3CA PPM1D POLD1 NTHL1 POLE ESR1 POT1 MC1R MITF WRN CHEK2 APC BARD1 MLH1 PRKAR1A CASP10 NBN PRKCD COL14A1 AKT1 C11ORF95 PRKN RELA MSH2 FGFR2 IDH1 GNAS IDH2 CTNNB1 RB1CC1 PTEN MDM2 FAS FASLG AAGAB CDH1 TERT RNF43 PALLD PALB2 OPCML TERF2IP PRLR SEC23B TP53 SDHB SDHC SDHD SMAD4 BAP1 CDK4 TWIST1 RAD50
Neoplasm of the lung
Genes 43
WT1 KRAS SLC22A18 STK11 IRF1 AKT1 C11ORF95 PRKN PPP2R1B ERBB2 TRPV3 TSC1 POU6F2 TSC2 EWSR1 RELA KEAP1 REST DIS3L2 SFTPA2 GPC3 MBTPS2 LMNA PTEN BRAF BRCA2 EGFR RB1 TRIP13 PDGFRB TERT SFTPC PIK3CA TRIM28 DICER1 MAP3K8 HPGD SLCO2A1 H19 TP53 NOTCH3 BAP1 WRN